Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celltrion, Inc.
Celltrion has kicked off plans for a Phase III trial for its denosumab biosimilar rival to Prolia.
Companies will raise their COVID-19 vaccine prices once the pandemic is over – but key long-term data will determine which comes out on top.
The International Generic and Biosimilar Medicines Association has named the IPA’s Sudarshan Jain as its new chair. While Celltrion’s chairman has stepped down, Coherus has added two members to its board of directors and Synthon has appointed a new CEO.
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.